After 90 days of ADT, the proportions of patients receiving hyperlipidemia or cardiac treatments were significantly lower in the GnRH antagonist than GnRHa-treated group (hyperlipidemia treatment: 25.1% vs 34.3%, respectively; p < 0.0001; cardiac therapy: 24.6% vs 32.8% respectively; p < 0.0001). The gene discussed is GNRH1; the disease is hyperlipidemia.